Inspira Accelerates U.S. Commercial Strategy: FDA-Cleared ART100 Targets Market Adoption at AmSECT 2026 via Glo-Med Networks
MWN-AI** Summary
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) is set to showcase its FDA-cleared INSPIRA™ ART100 system at the upcoming American Society of Extracorporeal Technology (AmSECT) 64th International Conference in Austin, Texas, from March 25–29, 2026. This strategic presentation, managed via its U.S. distributor Glo-Med Networks Inc., aims to engage clinical decision-makers within the perfusion and cardiac surgical community, significantly influencing hospital purchasing decisions.
The ART100 has gained attention due to its FDA 510(k) clearance acquired in May 2024, which underscores its readiness for clinical integration into cardiopulmonary bypass procedures. With the AmSECT conference being a hub for innovations in perfusion technology, Inspira expects to boost market visibility and establish critical clinical partnerships that are essential for their U.S. commercial strategy.
Mike Hershkovitz, Global VP Sales at Inspira, emphasized the importance of the conference, stating that it serves as a key juncture for translating FDA approval into tangible market share. The company aims to capitalize on its active distribution channels and showcase the ART100's capabilities to a targeted audience, bolstering its foothold in the MedTech landscape.
Inspira Technologies continues to expand its product range with advancements such as the next-generation INSPIRA ART500 and the HYLA™ blood sensor platform, making it a compelling player in life-support and respiratory support segments. As the company progresses, healthcare leaders and industry stakeholders are encouraged to schedule meetings for in-depth discussions regarding the ART100 and future collaborations. For more details, visit Inspira's official website or contact the company directly.
MWN-AI** Analysis
Inspira Technologies’ recent announcement regarding the showcase of its FDA-cleared INSPIRA™ ART100 system at the AmSECT 2026 International Conference marks a pivotal moment in the company's U.S. commercial strategy. As financial analysts observe, this event offers a significant opportunity for Inspira to enhance its visibility and catalyze market adoption among key decision-makers in the medical field.
The ART100 system, cleared for cardiopulmonary bypass procedures, addresses a critical need for advanced life-support technologies within U.S. hospitals. Its introduction at AmSECT provides a platform to engage directly with perfusionists and cardiac surgical teams, who are instrumental in influencing hospital purchasing decisions. This strategic positioning should not be underestimated, as penetrating established hospital supply chains can be both challenging and rewarding.
With its strong FDA clearance secured in May 2024, Inspira is positioned to capitalize on its regulatory approval by actively demonstrating the ART100's clinical benefits and operational efficiencies. Moreover, partnerships with distributors like Glo-Med Networks facilitate an efficient route to market, enabling Inspira to swiftly transition from product development to sales execution, thereby reducing the time to revenue.
Investors should note that the U.S. medical device market is highly competitive, with numerous players and rapid technological advancements. Although Inspira is building a promising commercial pipeline with multiple cleared products, factors such as market adoption rates and potential challenges in scaling operations will be crucial in determining the company's success. Therefore, while the growth prospects are encouraging, cautious optimism should prevail.
In light of these developments, investors may consider taking a closer look at Inspira Technologies (NASDAQ: IINN, IINNW) as it embarks on this pivotal phase, keeping an eye on further updates from the AmSECT conference and subsequent market performance.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
RA'ANANA, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira Technologies,” “Inspira,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic commercial showcase of its U.S. Food and Drug Administration (“FDA”)-cleared INSPIRA™ ART100 system. The system will be featured at the American Society of Extracorporeal Technology (AmSECT) 64th International Conference, taking place March 25–29, 2026, in Austin, Texas, at the exhibition booth of its U.S. distributor, Glo-Med Networks Inc. (“Glo-Med”).
Key Commercial Highlights:
- Targeting Clinical Decision Makers: The ART100 will be positioned at AmSECT, the premier global venue for perfusionists and cardiac surgical teams who directly influence hospital purchasing decisions.
- Leveraging FDA Clearance: The showcase capitalizes on the ART100’s FDA 510(k) clearance (received in May 2024) to validate the system’s readiness for immediate clinical integration in cardiopulmonary bypass procedures.
- Active Distribution Channel: The presentation via Glo-Med demonstrates an active commercial pipeline, moving beyond development into sales execution and market visibility.
“We are moving fast to translate our FDA clearance into market share. Presenting the ART100 alongside Glo-Med at AmSECT allows us to engage directly with the decision-makers who drive hospital purchasing,” said Mike Hershkovitz, Global VP Sales at Inspira Technologies. “This event marks a key phase in our U.S. commercial strategy as we expand our clinical partnerships and distribution footprint.”
Commercial and Clinical Inquiries Perfusion leaders, hospital administrators, and industry partners interested in scheduling a meeting with Mr. Hershkovitz during the conference are invited to contact: mike@inspirao2.com.
About the 64th AmSECT International Conference
The AmSECT International Conference is the definitive global event for perfusion technology. Taking place March 25–29, 2026, in Austin, Texas, the conference features cutting-edge medical technologies and expert-led sessions shaping the future of extracorporeal circulation and patient care.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com.
Forward-Looking Statements
This press release contains express or implied forward-looking statements pursuant to U.S. federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses benefits and advantages of the ART100 system, its active commercial pipeline, the move into sales execution and market visibility and that it is actively expanding its clinical partnerships and distribution footprint in the U.S.. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC's website at www.sec.gov.
Company Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485
FAQ**
How does Inspira Technologies Oxy B.H.N. Ltd. IINN plan to leverage its FDA-cleared ART100 system to capture market share within the U.S. cardiopulmonary bypass sector following its showcase at AmSECT?
What specific feedback has Inspira Technologies Oxy B.H.N. Ltd. IINN received from clinical decision makers during previous exhibitions that might inform their strategy at the upcoming AmSECT conference?
Can you elaborate on the strategic partnerships Inspira Technologies Oxy B.H.N. Ltd. IINN is pursuing to enhance its distribution footprint and clinical collaboration in the U.S. market?
What are the potential risks identified in Inspira Technologies Oxy B.H.N. Ltd. IINN's forward-looking statements regarding the ART100 system that could impact its commercialization and market execution?
**MWN-AI FAQ is based on asking OpenAI questions about Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN).
NASDAQ: IINN
IINN Trading
-2.18% G/L:
$0.58 Last:
47,279 Volume:
$0.594 Open:
